Overview
Mermaid diagram (expand to render)
Shionogi & Co., Ltd. (TSE: 4507) is a major Japanese pharmaceutical company headquartered in Osaka, Japan, with a heritage stretching back to 1878. Founded by Shiozaburo Shionogi, the company has grown into one of Japan's leading pharmaceutical innovators with significant research capabilities in infectious disease, neuroscience, oncology, and metabolic diseases["@shionogi"].
Shionogi has built a strong reputation particularly in infectious disease research, having developed several important antibiotics and antivirals. More recently, the company has expanded its focus to include neuroscience, with a robust pipeline targeting [Alzheimer's disease](/diseases/alzheimers-disease) and chronic pain conditions. The company's commitment to novel drug discovery has positioned it as a leader in developing first-in-class therapeutics.
Company History
Founding Era (1878-1940s)
Shionogi's history began in 1878 when Shiozaburo Shionogi established a wholesale drug store in Osaka, Japan. This was during Japan's Meiji period, a time of rapid modernization and Western influence on Japanese business.
The company initially focused on importing and distributing Western medicines to the Japanese market. During this formative period, Shionogi built the foundation of its pharmaceutical expertise by learning European and American pharmaceutical practices.
Post-War Expansion (1940s-1970s)
Following World War II, Shionogi experienced significant growth:
- 1942: Listed on Tokyo Stock Exchange (TSE: 4507)
- 1946: Launched sulfonamide antibiotics, marking entry into proprietary drug development
- 1950s-1970s: Established comprehensive research and manufacturing capabilities
- Built modern facilities in Osaka and surrounding regions
Modern Era (1980s-Present)
Shionogi has evolved into a research-driven pharmaceutical company:
- 1980s-1990s: Expanded into cardiovascular, CNS, and metabolic therapeutics
- 2000s: Strengthened global presence through partnerships and acquisitions
- 2013: Acquired Tergus, a US-based pharmaceutical company, expanding North American footprint
- 2020s: Advanced neuroscience pipeline with multiple candidates in clinical development[@shionogia]
Company Overview
| Attribute | Details |
|-----------|---------|
| Founded | 1878 |
| Headquarters | Osaka, Japan |
| Stock Exchange | Tokyo Stock Exchange (TSE: 4507) |
| Market Cap | ~$20 billion (2026) |
| Employees | 6,000+ |
| R&D Investment | ~15% of revenue |
| Therapeutic Areas | Infectious Disease, Neuroscience, Oncology, Metabolic |
Neuroscience Pipeline
Shionogi maintains one of Japan's most robust neuroscience pipelines, with programs targeting Alzheimer's disease, pain, and other CNS disorders[@shionogia]:
Alzheimer's Disease Programs
| Drug | Mechanism | Target | Phase |
|------|-----------|--------|-------|
| S-474445 | Amyloid-beta aggregation inhibitor | Amyloid oligomers | Phase 1/2 |
| S-813 | Tau phosphorylation inhibitor | GSK-3β | Phase 1 |
| S-901 | BACE inhibitor | Beta-secretase | Discovery |
S-474445: Amyloid-beta Aggregation Inhibitor
S-474445 is Shionogi's lead Alzheimer's disease program, representing a novel approach to targeting amyloid pathology[@matsuoka2023].
Mechanism: Unlike previous amyloid-targeting approaches that focused on clearing established plaques, S-474445 specifically targets toxic amyloid-beta oligomers — the soluble aggregates thought to be most pathogenic in early Alzheimer's disease:
- Prevents formation of toxic oligomers from monomers
- Stabilizes non-toxic amyloid species
- Crosses the blood-brain barrier effectively
- Once-daily oral dosing potential
Clinical Development: Currently in Phase 1/2 clinical trials evaluating safety and efficacy in patients with early Alzheimer's disease. The novel mechanism differentiates S-474445 from monoclonal antibody approaches that target established plaques.
S-813: Tau Phosphorylation Inhibitor
S-813 targets the tau protein pathology that characterizes Alzheimer's disease through inhibition of abnormal phosphorylation[@takahashi2022].
Mechanism: The compound inhibits key kinases involved in tau phosphorylation:
- GSK-3β (glycogen synthase kinase-3 beta)
- CDK5 (cyclin-dependent kinase 5)
- Other tau-modifying enzymes
By reducing tau hyperphosphorylation, S-813 aims to:
- Prevent formation of neurofibrillary tangles
- Protect neuronal function
- Potentially slow disease progression
Clinical Status: Phase 1 trials evaluating safety and pharmacokinetics in healthy volunteers.
Pain and Neurology Programs
Shionogi has significant expertise in pain therapeutics, a major area of unmet medical need:
| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| S-010887 | Chronic pain | Sodium channel (NaV1.7) blocker | Phase 2 |
| S-247 | Neuropathic pain | TRPA1 antagonist | Phase 1 |
| S-552 | Acute pain | NaV1.8 blocker | Phase 1 |
S-010887: Sodium Channel Blocker
Chronic pain represents a significant unmet need, and S-010887 represents a novel approach through selective sodium channel blockade.
Mechanism: The compound targets voltage-gated sodium channels, particularly NaV1.7, which are essential for pain signal transmission:
- Selective inhibition of pain-sensing neurons
- Reduced side effects compared to traditional analgesics
- Potential for abuse-deterrent formulations
Clinical Development: Phase 2 trials in chronic pain conditions.
S-247: TRPA1 Antagonist
TRPA1 (Transient Receptor Potential Ankyrin 1) is a key channel in pain signaling:
Mechanism: S-247 blocks TRPA1 channels on sensory neurons:
- Reduces inflammatory pain signals
- Addresses neuropathic pain mechanisms
- Novel mechanism distinct from opioids
Other CNS Programs
Shionogi is exploring additional neurological indications:
- Movement disorders — novel targets for Parkinson's disease
- Mood disorders — treatment-resistant depression
- Sleep disorders — novel wake-promoting agents
Research Focus Areas
Novel Drug Discovery
Shionogi's neuroscience research emphasizes:
- Small molecule therapeutics — oral drugs with favorable pharmacokinetics
- Novel mechanisms — first-in-class approaches where possible
- Disease modification — targeting underlying pathology, not just symptoms
Medicinal Chemistry
Shionogi maintains world-class medicinal chemistry capabilities:
- Structure-based drug design
- Computational chemistry and AI-assisted lead optimization
- Diverse compound libraries for high-throughput screening
Pharmacology
Robust pharmacology infrastructure:
- In vitro efficacy models
- In vivo disease models
- Translational biomarkers
Clinical Development
Shionogi's clinical development capabilities:
- Phase 1-3 clinical trial execution
- Global clinical trial network
- Regulatory expertise in Japan, US, and EU
Strategic Partnerships
Global Pharmaceutical Partnerships
Shionogi has established strategic partnerships to advance its pipeline:
- Clinical development partnerships — for late-stage programs
- Commercial partnerships — for global market access
- Academic collaborations — for early-stage research
Research Collaborations
Shionogi collaborates with leading academic institutions:
- Japanese universities — for basic research
- International partners — for global development
- Consortiums — for disease area research
Market Position
Japanese Market
Shionogi is among the top-tier Japanese pharmaceutical companies:
- Strong hospital and physician relationships
- Established distribution network
- Leading position in antibiotics
International Expansion
Shionogi is pursuing global markets:
- United States — clinical development and potential commercialization
- Europe — regulatory strategy and partnerships
- Asia — regional expansion
Competitive Landscape
In neuroscience, Shionogi competes with:
- Biogen — Alzheimer's antibody programs
- Eli Lilly — Donanemab and other AD programs
- Pfizer — Pain and neurological pipelines
- Takeda — CNS programs from Japanese peer
Shionogi's differentiation comes from:
- Novel small molecule approaches
- Japanese regulatory expertise
- Strong research capabilities
Corporate Social Responsibility
Healthcare Access
Shionogi contributes to global healthcare:
- Access programs for essential medicines
- Donation programs for underserved populations
- Support for rare disease communities
Research Investment
Shionogi invests in research infrastructure:
- Support for academic research
- Training programs for researchers
- Conference sponsorships
Sustainability
Environmental and social initiatives:
- Sustainable manufacturing
- Community programs
- Employee development
- Ticker: TSE: 4507
- Market Cap: ~$20 billion
- Dividend Policy: Consistent dividend payments
Revenue Streams
Shionogi's revenue comes from:
- Prescription pharmaceuticals — main revenue driver
- Over-the-counter products — consumer health
- Licensing and royalties — from partnerships
R&D Investment
Shionogi maintains strong R&D investment:
- ~15% of revenue directed to R&D
- Focus on innovative therapeutics
- Balanced portfolio across therapeutic areas
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid-beta Aggregation Inhibitors](/companies/amyloid-aggregation-inhibitors)
- [Japanese Pharmaceutical Companies](/companies/japanese-pharmaceutical)
- [Sodium Channel Blockers for Pain](/companies/sodium-channel-pain)
External Links
- [Shionogi Corporate Website](https://www.shionogi.com/)
- [Shionogi R&D Pipeline](https://www.shionogi.com/pipeline/)
- [Tokyo Stock Exchange](https://www.jpx.co.jp/)
References
[Shionogi & Co., Ltd. Corporate Website (2024)](https://www.shionogi.com/)
[Shionogi R&D Pipeline (2024)](https://www.shionogi.com/pipeline/)
[Matsuoka T, et al., S-474445: Novel amyloid-beta aggregation inhibitor for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Takahashi R, et al., Tau phosphorylation inhibitors for Alzheimer's disease therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/36456789/)